Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 29 of 2867 for:    Pancreatic Cancer

Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00885248
Recruitment Status : Unknown
Verified April 2009 by Asan Medical Center.
Recruitment status was:  Active, not recruiting
First Posted : April 21, 2009
Last Update Posted : April 21, 2009
Sponsor:
Information provided by:
Asan Medical Center

Tracking Information
First Submitted Date April 20, 2009
First Posted Date April 21, 2009
Last Update Posted Date April 21, 2009
Study Start Date January 2009
Estimated Primary Completion Date November 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 20, 2009)
Staging of pancreatic cancer [ Time Frame: 6 months after study start ]
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: April 20, 2009)
Diagnosis of pancreatic cancer [ Time Frame: 6 months after study start ]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer
Official Title Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer
Brief Summary

In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed.

After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available.

In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.

Detailed Description Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the gold standard for pancratic cancer is operative specimen. If the operation can't be performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will be preferred to laparotomy.
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population The suspects of pancreatic cancer to visit Asan Medical Center in South Korea
Condition Pancreatic Cancer
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: April 20, 2009)
70
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2009
Estimated Primary Completion Date November 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Pancreatic mass suspicious of pancreatic cancer
  • No comorbidity, expected life expectancy less than 6 months
  • Consent this study in letter

Exclusion Criteria:

  • Refuse diagnostic and staging work-up
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Korea, Republic of
Removed Location Countries  
 
Administrative Information
NCT Number NCT00885248
Other Study ID Numbers 2008-0623
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Myung-Hwan Kim, Department of Internal Medicine, Asan Medical Center
Study Sponsor Asan Medical Center
Collaborators Not Provided
Investigators Not Provided
PRS Account Asan Medical Center
Verification Date April 2009